A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma
Clinical trial NCT07567469 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07567469
- Sponsor
- Regeneron Pharmaceuticals
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-08-31
- Primary completion
- 2032-08-27
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.